Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pre-operative ribociclib plus letrozole versus chemotherapy: Health-related quality of life outcomes from the SOLTI CORALLEEN trial.
Villacampa G, Falato C, Paré L, Hernando C, Arumí M, Saura C, Gómez G, Muñoz M, Gil-Gil M, Izarzugaza Y, Ferrer N, Najera-Zuloaga J, Montaño A, Ciruelos E, González-Santiago S, Villagrasa P, Gavilá J, Prat A, Pascual T. Villacampa G, et al. Among authors: gavila j. Eur J Cancer. 2022 Oct;174:232-242. doi: 10.1016/j.ejca.2022.07.028. Epub 2022 Sep 5. Eur J Cancer. 2022. PMID: 36067616 Clinical Trial.
A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole.
Garcia-Casado Z, Guerrero-Zotano A, Llombart-Cussac A, Calatrava A, Fernandez-Serra A, Ruiz-Simon A, Gavila J, Climent MA, Almenar S, Cervera-Deval J, Campos J, Albaladejo CV, Llombart-Bosch A, Guillem V, Lopez-Guerrero JA. Garcia-Casado Z, et al. Among authors: gavila j. BMC Cancer. 2010 Feb 9;10:36. doi: 10.1186/1471-2407-10-36. BMC Cancer. 2010. PMID: 20144226 Free PMC article.
SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer.
Llombart-Cussac A, Bermejo B, Villanueva C, Delaloge S, Morales S, Balmaña J, Amillano K, Bonnefoi H, Casas A, Manso L, Roché H, Gonzalez-Santiago S, Gavilá J, Sánchez-Rovira P, Di Cosimo S, Harbeck N, Charpentier E, Garcia-Ribas I, Radosevic-Robin N, Aura C, Baselga J. Llombart-Cussac A, et al. Among authors: gavila j. Breast Cancer Res Treat. 2015 Nov;154(2):351-7. doi: 10.1007/s10549-015-3616-8. Epub 2015 Nov 4. Breast Cancer Res Treat. 2015. PMID: 26536871 Free PMC article. Clinical Trial.
SEOM clinical guidelines in metastatic breast cancer 2015.
Gavilá J, Lopez-Tarruella S, Saura C, Muñoz M, Oliveira M, De la Cruz-Merino L, Morales S, Alvarez I, Virizuela JA, Martin M. Gavilá J, et al. Clin Transl Oncol. 2015 Dec;17(12):946-55. doi: 10.1007/s12094-015-1476-7. Epub 2015 Dec 18. Clin Transl Oncol. 2015. PMID: 26683474 Free PMC article.
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET).
Jerusalem G, Mariani G, Ciruelos EM, Martin M, Tjan-Heijnen VC, Neven P, Gavila JG, Michelotti A, Montemurro F, Generali D, Simoncini E, Lang I, Mardiak J, Naume B, Camozzi M, Lorizzo K, Bianchetti S, Conte P. Jerusalem G, et al. Among authors: gavila jg. Ann Oncol. 2016 Sep;27(9):1719-25. doi: 10.1093/annonc/mdw249. Epub 2016 Jun 29. Ann Oncol. 2016. PMID: 27358383 Free article. Clinical Trial.
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain.
Ciruelos E, Vidal M, Martínez de Dueñas E, Martínez-Jáñez N, Fernández Y, García-Sáenz JA, Murillo L, Carabantes F, Beliera A, Fonseca R, Gavilá J. Ciruelos E, et al. Among authors: gavila j. Clin Transl Oncol. 2018 Jun;20(6):753-760. doi: 10.1007/s12094-017-1784-1. Epub 2017 Nov 7. Clin Transl Oncol. 2018. PMID: 29116433 Clinical Trial.
Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial.
Gavilá J, Oliveira M, Pascual T, Perez-Garcia J, Gonzàlez X, Canes J, Paré L, Calvo I, Ciruelos E, Muñoz M, Virizuela JA, Ruiz I, Andrés R, Perelló A, Martínez J, Morales S, Marín-Aguilera M, Martínez D, Quero JC, Llombart-Cussac A, Prat A. Gavilá J, et al. BMC Med. 2019 Jan 9;17(1):8. doi: 10.1186/s12916-018-1233-1. BMC Med. 2019. PMID: 30621698 Free PMC article. Clinical Trial.
SEOM clinical guidelines on cardiovascular toxicity (2018).
Virizuela JA, García AM, de Las Peñas R, Santaballa A, Andrés R, Beato C, de la Cruz S, Gavilá J, González-Santiago S, Fernández TL. Virizuela JA, et al. Among authors: gavila j. Clin Transl Oncol. 2019 Jan;21(1):94-105. doi: 10.1007/s12094-018-02017-3. Epub 2019 Jan 9. Clin Transl Oncol. 2019. PMID: 30627982 Free PMC article.
47 results